WW International’s Subscriber Growth Projections and Clinical Trajectory Contradictions Emerge in 2025 Q4 Earnings Call

Date of Call: Mar 16, 2026

Financials Results

• Revenue: $163M in Q4, down 12% YOY, with 32% growth in clinical revenue and 17% decline in behavioral revenue
• Gross Margin: Adjusted gross margin of 74.4% in Q4, slightly declined compared to Q3
• Operating Margin: Adjusted EBITDA margin of 11.1% in Q4

Guidance:

• Revenue for fiscal year 2026 expected to be in the range of $620M-$635M.
• Adjusted EBITDA for fiscal year 2026 expected to be in the range of $105M-$115M.
• Marketing expense as a percentage of revenue expected to increase modestly in 2026 compared to 2025.
• Product development expenses expected to remain at a similar quarterly run rate to the second half of 2025.
• Modest SG&A savings expected in 2026, primarily driven by exiting the corporate headquarters lease.
• Q1 cash usage expected to be meaningful, with capital expenditures and interest payments consistent with Q4 levels.

Business Commentary:

Financial Performance and Strategic Focus:

• Weight Watchers reported revenue of $163 million for Q4 2025, reflecting a 12% year-on-year decline, with a 32% growth in clinical revenue and a 17% decline in behavioral revenue.
• The company over-delivered on its previously provided 2025 guidance, with adjusted EBITDA of $18 million, marking an adjusted EBITDA margin of 11.1%.
• The financial performance was influenced by a strategic shift towards clinical offerings and the impact of a change in the fiscal reporting calendar, which included additional marketing spend.

Clinical Subscriber Growth:

• The number of end-of-period clinical subscribers reached 130,000 by the end of Q4 2025, with expectations to end Q1 2026 with approximately 200,000, representing roughly 100% year-over-year growth when adjusted for previous compounded semaglutide offerings.
• This growth is attributed to the increasing adoption of GLP-1 medications and the successful launch of the Wegovy pill, which has expanded the company's addressable market.

Behavioral Subscriber Trends:

• End-of-period behavioral subscribers were 2.6 million at the end of Q4 2025, with expectations to decline to approximately 2.45 million by the end of Q1 2026, a decrease of 26% year-over-year.
• The decline is due to multi-year secular headwinds and strategic prioritization of clinical offerings, although there is a focus on transitioning members to higher-value premium offerings like Core+.

Marketing and Brand Perception:

• Marketing expenses accounted for 40% of Q4 revenue, increasing year-over-year due to the inclusion of peak season marketing spend from the new fiscal reporting calendar.
• The brand repositioning efforts, aimed at driving awareness of the Med+ offering, resulted in a 35% increase in first-time U.S. members and improved brand modernization perception by 9 points.

Technology and Product Development:

• The company has been focusing on modernizing its technology infrastructure, with product development expenses at 5% of Q4 revenue.
• The relaunch of the mobile app in January and ongoing updates reflect a commitment to enhancing the user experience and integrating new digital tools to support member engagement.

Sentiment Analysis:

Overall Tone: Positive

• CEO stated 'We answer that question with a resounding yes' regarding successful reinvention. She noted 'We have never been more confident in our ability to succeed' and that 'momentum strengthens further into Q1' with clinical subscribers reaching new highs. The tone was optimistic about strategic progress and market response.

Q&A:

• Question from Alex Fuhrman (Lucid Capital Markets): Can you talk about demand for the Wegovy pill and how we should think about the next 3-6 months now that you're lapping the compounded GLP-1s?
  Response: Demand for Wegovy has exceeded initial projections, expanding the total addressable market by attracting new patients to obesity medicine. The launch is viewed as validating Weight Watchers' position as a leader in the weight health space, with a clinically agnostic infrastructure built to evolve with the science.

• Question from Alex Fuhrman (Lucid Capital Markets): How does the 50% of new Med+ members being brand new compare to past clinical growth, and what's driving new interest?
  Response: The 50% figure is positive for brand repositioning, driven by the strength of the Weight Watchers brand and efforts to raise awareness of its clinical offerings. It reflects a strategic shift to attract new members and re-engage lapsed ones, with early success in changing perceptions.

• Question from Justin Ages (CJS Securities): Is the demographic of new Weight Watchers members different now, and are you seeing any shift in contract length?
  Response: New demographics include younger members and lapsed members returning, with trends expected to widen over time. There is a positive trend toward longer-term contracts (LTCs), especially in the clinical business, which is being tested and learned as part of the product architecture reset.

• Question from William Reuter (Bank of America): What are your pricing strategy and promotional plans for 2026, and how important is ARPU versus increased numbers?
  Response: Strategy includes allowing members to renew from LTC to LTC, which may slightly impact ARPU but supports retention. Promotional activity is used deliberately, with a focus on mix shift to clinic and Core+ which command higher ARPU, leading to expected ARPU expansion over time.

• Question from William Reuter (Bank of America): Can you share data points on the B2B initiative's success and growth expectations?
  Response: The B2B business, though still a small percentage of total revenue, shows promising momentum and pipeline activity post-bankruptcy. It provides diversification, with initiatives like expanding partnerships with UnitedHealth Group and the RxFlexFund program offering employer subsidies for GLP-1s.

Contradiction Point 1

Subscriber Growth Momentum and Outlook

Contradiction on whether the company is expecting strong growth momentum or facing near-term headwinds.

Alex Fuhrman (Lucid Capital Markets) - Alex Fuhrman (Lucid Capital Markets)

2025Q4: Q1 2026 subscriber growth is expected to be 100% year-over-year. - [Felicia DellaFortuna](CFO)

How should we assess demand for Wegovy and the next 3-6 months now that you're lapping the compounded GLP-1 period? - Nathaniel Feather (Morgan Stanley)

2025Q3: The company faces an acquisition headwind in 2026 due to the behavioral business challenges. - [Felicia DellaFortuna](CFO)

Contradiction Point 2

Clinical Subscriber Growth Trajectory

Conflicting signals on subscriber growth momentum in the clinical business.

Alex Fuhrman (Lucid Capital Markets) - Alex Fuhrman (Lucid Capital Markets)

2025Q4: Stripping out the impact of the compounded semaglutide offering in Q1 2025, Q1 2026 subscriber growth is expected to be 100% year-over-year. - [Felicia DellaFortuna](CFO)

How should we assess demand for Wegovy and the next 3-6 months given the lapping of the compounded GLP-1 period? - Nathaniel Jay Feather (Morgan Stanley)

2025Q2: The transition away from compounded semaglutide is ongoing through August 2025... A sequential decline in Clinical subscribers is expected in Q3 2025 compared to Q2, as the roll-off continues. - [Jon Volkmann](CEO)

Contradiction Point 3

B2B Business Outlook

Differing characterizations of the B2B channel's current state and growth potential.

Can you discuss the company's earnings results for the quarter? - William Reuter (Bank of America)

2025Q4: The B2B business was impacted by the bankruptcy as it has a long sales cycle. Since then, the pipeline is active and promising... - [Felicia DellaFortuna](CFO)

What data points can you share regarding the B2B initiative's success, size, and growth expectations for this year? - Nathaniel Jay Feather (Morgan Stanley)

2025Q2: The channel was impacted by bankruptcy-related headlines in Q2, but momentum is regaining... - [Tara M. Comonte](CEO)

Contradiction Point 4

Product Strategy and Market Positioning

The brand's growth strategy shifts from focusing on product innovation to emphasizing clinical offerings and rebranding.

Alex Fuhrman (Lucid Capital Markets) - Alex Fuhrman (Lucid Capital Markets)

2025Q4: The 50% figure is encouraging for the brand's repositioning. It reflects a multi-pronged strategy: leveraging the strong global awareness of the Weight Watchers brand while raising awareness of its new clinical offerings. - [Tara Comonte](CMO)

How does the current 50% of new Med+ members being new to the brand compare to past clinical growth, and what is driving the increased interest from new users? - Nathaniel Feather (Morgan Stanley)

2024Q4: Product enhancements (e.g., AI food scanner, macro tracking) led to a highest activation rate since 2020 and improved brand metrics, which are positive leading indicators for future growth, though not immediately reflected in top-line revenue. - [Tara Comonte](CMO)

Contradiction Point 5

Growth Outlook and Subscriber Metrics

Q1 2026 subscriber growth projections show a significant upward revision.

Alex Fuhrman (Lucid Capital Markets) - Alex Fuhrman (Lucid Capital Markets)

2025Q4: Stripping out the impact of the compounded semaglutide offering in Q1 2025, Q1 2026 subscriber growth is expected to be 100% year-over-year. - [Felicia DellaFortuna](CFO)

How should we assess demand for Wegovy and the next 3-6 months as you lap the compounded GLP-1 period? - Michael Lasser (UBS)

2024Q4: While behavioral subscriber recruitment remains challenging, ARPU hit a record high of $4 in Q4 due to a higher mix of Clinical subscribers. - [Felicia DellaFortuna](CFO)